Company ProfilePremium

Aspira Pathlab & Diagnostics Limited

Company Profile Analysis

Ticker: 540788.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aspira Pathlab & Diagnostics Limited - Company showcase

Year Founded & Workforce

1973

141 Employees

Aspira Pathlab & Diagnostics Limited logo

Aspira Pathlab & Diagnostics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aspira Pathlab & Diagnostics Limited Overview

FieldDetail
Entity profiledAspira Pathlab & Diagnostics Limited (same entity as the one on the input list; no relisting or merger)
Legal nameAspira Pathlab & Diagnostics Limited
Former nameUtkal Soap Products Limited (name changed 16 November 2016)
Date of incorporation3 July 1973
Original state of registrationWest Bengal (registered office moved to Maharashtra by order dated 18 November 2016)
Corporate Identification Number (CIN)L85100MH1973PLC289209
Registrar of CompaniesRoC Mumbai
Registered officeFlat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (West), Mumbai 400 086, Maharashtra, India
Corporate office (as disclosed in 2019 filings)Plot No. 6, RPT House, Sector 24, Turbhe, Navi Mumbai 400 703 (current status not re-verified)
Primary listingBSE Limited. Scrip code 540788; Security ID ASPIRA
Other tickersYahoo: ASPIRA.BO; Reuters: ASPR.BO; some broker sites show NSE symbol "ASPIRA"
Historical listingsCalcutta Stock Exchange and Metropolitan Stock Exchange of India (both delisted)
ISININE500C01017
CUSIPNot applicable (Indian security)
Face value₹10 per share
Shares outstanding1,02,93,000 equity shares (10.293 million). Equity share capital ₹10.29 Cr per the open-offer filing. One company-registry aggregator shows paid-up capital of ₹15.79 Cr against authorised capital of ₹35.00 Cr. This discrepancy is unreconciled and could reflect a post-June-2026 allotment or an aggregator error.
Fiscal year end31 March
Statutory auditorrefer to the FY2025-26 Annual Report
Registrar and Transfer AgentLink Intime (India) Pvt Ltd per FY2021-22 Annual Report (previously Sharex Dynamic (India) Pvt Ltd in FY2018-19)
Banker (FY2021-22 AR)Bank of Baroda
Websitewww.aspiradiagnostics.com
Brand taglines"Predict • Prevent • Protect"; "India's First Fully Integrated Lab" (company letterhead)
MetricFY2024FY2025FY2026
Employees (count)——141

The 141 figure is PitchBook's profile count as of 2026.

Market Value (Latest)

MetricValue
Closing share price (BSE, 19 Oct 2026)₹114.95
Market capitalisation (derived: ₹114.95 × 1.0293 Cr shares)approx. ₹118 Cr (approx. USD 14 million)
52-week high / low (as of mid-2026)₹135.88 / ₹49.00
Promoter holding (June 2026)46.58%

Aspira Pathlab & Diagnostics is a Mumbai-based micro-cap pathology and radiology services company. It operates through a shell-company route: a 1973 West Bengal soap manufacturer, Utkal Soap Products, was repurposed in 2016 by acquiring the running business of Ankur Pathology Laboratory. The company runs diagnostic centres concentrated in Mumbai, chiefly Ghatkopar and the eastern suburbs. Its services span pathology (biochemistry, haematology, histopathology, microbiology, immunology, virology, cytology), radiology (X-ray, ultrasound), and cardiology investigations. It serves walk-in and home-collection patients (B2C), plus hospitals, laboratories and corporates (B2B), including a growing Hospital Lab Management (HLM) offer. With FY2026 revenue of ₹24.98 Cr and near-breakeven profit, Aspira is a sub-scale regional player in a market dominated by national chains such as Dr Lal PathLabs and Metropolis. In 2026 its ownership was reshaped by a ₹55-per-share SEBI open offer that consolidated control with the Bhanushali–Mange family group. The company is now planning a rights issue of up to ₹65 Cr.


What the Company Does

Aspira's exchange-filed description says it is engaged in running, owning, managing and administering diagnostic centres. Its principal activities are pathology investigation services, radiology investigation services and related healthcare services at diagnostic centres in Mumbai. Its corporate profile describes it as a pathology specialist serving individual patients, hospitals, other healthcare providers and businesses. The profile says the company is built on technological automation, a patient-centric approach and dependable results. It also states an intention to establish itself as a strong regional player before scaling up. The company claims a "pan-India presence" in some profile text, but the operating disclosures point to a Mumbai and Maharashtra concentration. We treat the regional description as the accurate one.

Business Model

The company operates a classic hub-and-spoke diagnostics model:

Hub (processing laboratory): a central lab in Mumbai where samples are processed on automated analysers. Company materials emphasise IT integration to cut human error and track samples.

Spokes (collection network): owned diagnostic centres, franchise or partner collection points, and home sample collection. One data provider states the company operates "over 600 centres" and added 91 locations in FY2024-25. These are almost certainly collection or touch points rather than full-service laboratories.

B2B channel: referral testing for hospitals, nursing homes, clinics and smaller laboratories, plus Hospital Lab Management (HLM). Under HLM, Aspira runs in-house laboratories for hospitals. Management commentary says it is targeting newly set-up hospitals and laboratories.

Digital initiatives: cited by management: a chatbot, website upgrades, a patient-engagement platform and customer-service improvements.

Revenue Model

Revenue typeDescriptionDisclosed share
Fee-for-service testing (B2C)Per-test or per-package fees from walk-in and home-collection patients—
B2B referral testingPer-test fees billed to hospitals, clinics and labs, usually at discounted B2B rates—
Hospital Lab Management (HLM)Service contracts to run hospital laboratories; may include revenue share or fixed fees—
Corporate and preventive healthWellness packages for employers and individuals—
Product, subscription, licensingNone identified0%

All revenue is service revenue. There is no product, subscription or licensing income.

Value Chain Position

Aspira sits at the service-delivery end of the diagnostics value chain. Upstream are in-vitro diagnostic (IVD) equipment and reagent suppliers, typically multinationals such as Roche, Abbott, Siemens Healthineers, Beckman Coulter and Sysmex. Downstream are referring doctors, hospitals and patients. With about ₹25 Cr of revenue, Aspira has limited bargaining power against reagent suppliers. It competes for doctor referrals against chains that are 50 to 100 times its size.

Customer Types and End-Markets

Customer typeNotes
Individual patientsWalk-in and home collection in Mumbai suburbs
Referring physiciansThe traditional standalone-lab referral model in Mumbai
Hospitals and nursing homesB2B referral plus HLM
Other laboratoriesOutsourced specialised tests
Corporates and businessesPre-employment and wellness testing

The end-market is the Indian diagnostics services market, specifically the Mumbai Metropolitan Region.

Independent Characterisation

Aspira is best described as a single-city, single-segment, sub-scale diagnostics operator with a listed-shell history. Its economics are highly sensitive to volume. Depreciation, much of it on right-of-use lease assets, runs at about ₹1.5 Cr per year against about ₹25 Cr of revenue. Small revenue swings therefore move it between double-digit operating margins and losses. This is visible in FY2024 (loss), FY2025 (profit) and FY2026 (breakeven). The FY2022 peak profit reflected COVID-era testing demand. The company's strategic future is now tied to the newly consolidated promoter group and the use of the proposed ₹65 Cr rights issue. That sum is more than 2.5 times annual revenue and about half the current market capitalisation.

Strategy

Stated Strategic Themes (from company descriptions and management commentary)

  1. Regional consolidation before scale-up. Build a strong regional (Mumbai and Maharashtra) franchise before expanding further.

  2. Hospital Lab Management (HLM) focus. Target newly established hospitals and laboratories.

  3. Technology and automation. Use automated analysers and IT-integrated sample tracking to cut human error.

  4. Digital patient engagement. Chatbot, website upgrade, patient-engagement platform and customer service.

  5. Preventive positioning. The "Predict • Prevent • Protect" brand architecture.

Initiatives in the Last 24 Months

DateInitiativeStatus / significance
Apr 2024Formed Aspira DNA Diagnostics Gujarat LLP (associate) for molecular / DNA diagnostics outside MumbaiReversed; strike-off decided May 2026
FY2025Network expansion of 91 locations (reported)Drove the 66.6% revenue rebound
FY2025–26Digital engagement tools (chatbot, platform)Ongoing; no metrics disclosed
Feb 2026Related-party transaction of up to ₹5 Cr with Yashraj Research FoundationApproved by Board; nature of services not disclosed; went to AGM for approval
Apr–Jun 2026Change of control via ₹55-per-share open offerCompleted; promoter stake 46.58%
Aug–Sep 2026Leadership transition to Nikunj Mange as MDCompleted Sep 2026
12 Sep 2026Rights issue of up to ₹65 Cr (equity or convertible instruments)Approved by Board; record date, price and objects pending

Medium-Term Targets and Guidance

The company has issued no quantitative financial guidance, medium-term targets, or cost-programme targets. No investor-day materials exist. No ESG or sustainability commitments have been publicly quantified.

Products & Services

Aspira does not publish a priced test menu in its regulatory filings. The catalogue below is compiled from the company's corporate descriptions and the service categories it lists. Specific test counts, pricing and launch years are not publicly disclosed in the filings reviewed.

Pathology Services

OfferingDescription / capabilitiesTarget customerPricing model
Clinical biochemistryRoutine chemistry panels (liver, kidney, lipid, glucose, electrolytes) on automated analysersB2C, B2B, HLMPer test / package
HaematologyCBC, coagulation and related blood testsB2C, B2BPer test
HistopathologyTissue biopsy processing and reportingHospitals, surgeonsPer specimen
CytologyPap smears, fluid cytology, FNACGynaecologists, hospitalsPer specimen
MicrobiologyCultures and sensitivity testingHospitals, cliniciansPer test
Immunochemistry / immunologyHormones, tumour markers, autoimmune panelsB2C, B2BPer test
Virology / serologyInfectious-disease serology; molecular testing capacity during COVID-19 (inferred from the FY2021–22 revenue spike; not separately disclosed)B2C, B2B, governmentPer test
DNA / molecular (Gujarat LLP initiative)Aspira DNA Diagnostics Gujarat LLP was formed in 2024, apparently for DNA-based testing; now being struck offB2B—

Radiology and Cardiology

OfferingDescriptionTarget customer
X-rayDigital radiography at diagnostic centresWalk-in patients, referrals
Ultrasound sonographyAbdominal, obstetric and general USGWalk-in patients, gynaecologists
Cardiology investigationsCardiac diagnostics (e.g., ECG; full menu not disclosed)Preventive packages, physicians

Channel and Service Offerings

OfferingDescription
Diagnostic centresOwned centres in Mumbai (Ghatkopar flagship near the railway station)
Collection networkReported 600+ centres or touch points, with 91 added in FY2025 (aggregator claim)
Home sample collectionDoorstep phlebotomy (typical of the model; specific disclosure limited)
Hospital Lab Management (HLM)Strategic focus area per management commentary; targets newly opened hospitals and labs
Preventive health packagesBundled wellness profiles under the "Predict • Prevent • Protect" positioning
Digital patient engagementChatbot, website, patient-engagement platform (management-stated initiatives)

Quality Credentials

A third-party (non-company) web page claims NABL and CAP accreditation. This could not be confirmed against an NABL certificate or company filing in this research run.

Financial Narrative

Sources: S&P Global Market Intelligence via StockAnalysis (income statement, balance sheet and cash flow, FY2022–FY2026, last updated 12 Aug 2026). Screener (consolidated FY2024–FY2025). Capital Market / Business Standard and Medical Buyer (FY2026 headline). Ratios are derived by this analyst from those figures. FY2021 revenue and profit are back-calculated from S&P's reported FY2022 growth rates (28.52% revenue, 222.91% net income) and are marked as derived.

Income Statement (₹ Cr)

Notes:

  • FY2021 (derived): revenue approx. ₹15.21 Cr; net income approx. ₹1.38 Cr.

  • Screener's consolidated FY2025 operating profit is ₹3.13 Cr (14.23% OPM) and FY2024 is -₹1.55 Cr. These differ from the S&P-derived EBITDA because of classification of other income and associate share. Both are shown for transparency.

  • FY2026 net profit was ₹5.13 lakh per the AGM disclosure (₹0.05 Cr).

  • The zero tax charge reflects accumulated losses: retained earnings were -₹12.0 Cr at FY2026.

Balance Sheet (₹ Cr, at 31 March)

Data-conflict note on equity. S&P shows "Total Common Equity" of ₹7.30 Cr (FY2026) and separately "Shareholders' Equity" of ₹12.23 Cr, a gap of about ₹4.9 Cr that S&P does not explain. Business Standard shows book value of ₹7.03 per share, consistent with the ₹7.3 Cr figure. Screener's P/B of about 9x implies book value nearer ₹12 per share, consistent with the ₹12.2 Cr figure. Ratios below use the ₹7.3 Cr common-equity figure, as it ties to share capital (₹10.29 Cr) plus premium (₹9.03 Cr) less accumulated deficit (₹12.02 Cr). Readers should confirm against the audited FY2026 balance sheet.

Goodwill. Goodwill of ₹2.65 Cr has sat on the books since the 2016 Ankur Pathology acquisition. It rose to ₹3.31 Cr in FY2026, alongside a ₹0.75 Cr cash acquisition outflow. The target of that FY2026 acquisition is not identified in the sources reviewed. It is possibly linked to the LLP buy-in or a centre or business purchase.

Key Ratios (Derived)

Net debt / EBITDA for FY2024 is NA because EBITDA was negative. Screener independently reports debtor days improving from 42.1 to 25.3, consistent with the derived figures.

Quarterly Run-Rate (₹ Cr)

Sources: Kotak Neo, IndMoney, roic.ai (Q2 FY2026), ScanX (Q3 FY2026, Q1 FY2027), Medical Buyer / Capital Market (Q4 FY2026).

Conflicts:

  • ScanX gives Q3 FY2025 profit as ₹0.38 Cr (₹37.66 lakh) against Kotak Neo's ₹0.31 Cr.

  • Univest gives Q4 FY2025 profit as ₹0.35 Cr against Capital Market's ₹0.72 Cr.

  • ScanX gives Q1 FY2026 revenue as ₹5.25 Cr (₹524.80 lakh) and profit as ₹0.47 Cr (₹46.94 lakh).

  • Q1 FY2027 revenue was ₹6.17 Cr (₹616.91 lakh), up about 17.6% YoY, while the net loss was ₹3.77 lakh. ScanX's headline said "revenue down 16%," but its own data show revenue up. The data figure is adopted here.

Commentary on Trends, Inflections and Drivers

Revenue. The five-year revenue line traces a COVID boom, normalisation, and a rebuild. FY2022 revenue of ₹19.54 Cr was lifted by pandemic testing. As this faded, revenue fell 26% in FY2023 and a further 8.7% in FY2024, to ₹13.21 Cr. The FY2025 rebound of 66.6%, to ₹22.00 Cr, was the inflection. It coincided with the reported addition of 91 locations and management's pivot toward HLM and B2B. FY2026 growth slowed to 13.6% (₹24.98 Cr). Within that, Q2 FY2026 was unusually strong at ₹8.09 Cr, possibly a lumpy B2B or institutional contract (not explained in filings reviewed), and Q3 FY2026 fell to ₹5.12 Cr. Quarterly volatility of this kind is typical of a company where a few institutional accounts can move the top line.

Profitability. Margins are dominated by operating leverage. Gross margin swung from 51% (FY2022) to 26% (FY2024) and back to about 41–44%. The FY2026 problem was below gross profit. Operating expenses excluding COGS jumped 36%, from ₹7.65 Cr to ₹10.42 Cr, while gross profit rose only 6.6%. This erased the FY2025 EBIT of ₹2.06 Cr. Likely contributors include network-expansion costs, staff costs, and costs around the change of control (open offer, governance changes, company-secretary turnover). The company has not provided a line-item explanation. Q3 and Q4 FY2026 losses of ₹1.56 Cr and ₹0.69 Cr confirm that the cost base outgrew revenue in the second half. Q1 FY2027 showed near-breakeven (-₹0.04 Cr) on higher revenue, suggesting some stabilisation.

Balance sheet. The balance sheet is small and modestly geared. Cash and short-term investments of about ₹1.7 Cr leave net debt of about ₹1.6 Cr. Working capital has shrunk from ₹5.4 Cr to ₹1.5 Cr, and the current ratio has fallen from 4.0x to 1.5x. Part of this is genuine improvement in collections: debtor days fell from 84 to 25. Part of it is cash being redeployed into long-term investments (₹2.79 Cr) and goodwill. The accumulated deficit of about ₹12 Cr means the company cannot pay dividends without first rebuilding reserves.

Cash flow. Cash generation is positive but thin. Operating cash flow has been positive in four of five years, at ₹1.0–2.0 Cr. However, after Ind AS 116 lease payments, which are effectively rent, true free cash flow was negative in FY2023 and FY2026. The business is not self-funding growth at scale. This frames the ₹65 Cr rights issue as a step-change in capital base rather than incremental funding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Segment Margins & Growth (%)

SegmentFY2024FY2025FY2026

Diagnostics services revenue (INR Cr)

13.2122.0024.98

Segment operating income, EBIT (INR Cr)

-2.732.06-0.08

Segment pre-tax income (INR Cr)

-2.672.020.05

Segment EBIT margin (%)

-20.69.4-0.3

YoY revenue growth (%)

-8.766.613.6

Share of total revenue (%)

100100100

Service Line Details

Service lineContent

Pathology

Biochemistry, haematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology

Radiology

X-ray, ultrasound sonography

Cardiology

Cardiac diagnostic investigations

Hospital Lab Management (HLM)

Outsourced operation of hospital labs

Preventive and corporate health

Packages and wellness programmes

Group Entities

EntityRelationshipStatus

Aspira Pathlab & Diagnostics Ltd

Listed parent and operating company

Active

Aspira DNA Diagnostics Gujarat LLP

Associate formed 2 Apr 2024; company to acquire 100% and strike off (announced May 2026)

Being wound up

Yashraj Biotechnology Ltd

Historical promoter-group shareholder (17.52% in 2018; 13.95% in Mar 2021); shared CEO in 2017–19

—

Yashraj Research Foundation

Counterparty to the ₹5 Cr related-party transaction approved by the Board on 10 Feb 2026

Related party

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

19.5414.4613.2122.0024.98

Revenue growth YoY (%)

28.5-26.0-8.766.613.6

Cost of revenue (INR Cr)

9.568.869.7912.2914.63

Gross profit (INR Cr)

9.985.593.429.7110.35

Operating expenses excl. COGS (INR Cr)

5.245.596.147.6510.42

Operating income, EBIT (INR Cr)

4.740.01-2.732.06-0.08

Depreciation & amortisation (INR Cr)

1.581.531.511.491.54

EBITDA, derived EBIT + D&A (INR Cr)

6.321.54-1.213.551.46

Interest expense (INR Cr)

0.310.370.320.310.39

Pre-tax income (INR Cr)

4.46-0.09-2.672.020.05

Tax (INR Cr)

00000

Net income (INR Cr)

4.46-0.09-2.672.020.05

EPS basic, derived on 1.0293 Cr shares (INR)

4.33-0.09-2.601.960.05

EPS diluted (INR)

4.33-0.09-2.601.960.05

Dividend per share (INR)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

51.138.725.944.141.4

EBITDA margin (%)

32.310.6-9.216.15.9

Operating (EBIT) margin (%)

24.20.1-20.69.4-0.3

Pre-tax margin (%)

22.8-0.6-20.29.20.2

Net margin (%)

22.8-0.6-20.29.20.2

CAGR

Value

————

Revenue CAGR FY2022–FY2026 (4 years)

6.3%————

Revenue CAGR FY2021–FY2026 (5 years, FY2021 derived)

10.4%————

Revenue CAGR FY2024–FY2026 (2 years)

37.5%————

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

18.1417.3414.7117.5118.51

Cash & short-term investments (INR Cr)

1.642.351.382.141.68

Trade receivables (INR Cr)

4.492.342.242.351.73

Inventory (INR Cr)

0.410.400.450.510.70

Property, plant & equipment incl. right-of-use (INR Cr)

6.825.314.123.863.88

Long-term investments (INR Cr)

0001.912.79

Goodwill & intangibles (INR Cr)

2.752.702.672.673.32

Short-term debt incl. current lease liabilities (INR Cr)

0.650.680.700.830.88

Long-term debt excl. leases (INR Cr)

0.860.961.081.211.35

Long-term lease liabilities (INR Cr)

2.421.681.011.161.09

Total debt incl. leases (INR Cr)

3.923.312.783.203.32

Net debt (INR Cr)

2.280.961.401.051.64

Total common equity (INR Cr)

7.867.825.217.297.30

Working capital (INR Cr)

5.364.272.282.991.47

Book value per share (INR)

7.647.605.077.087.09

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

2.03-0.011.051.881.45

Capital expenditure (INR Cr)

-0.60-0.13-0.26-0.34-0.70

Free cash flow (INR Cr)

1.43-0.140.791.530.76

Lease payments (INR Cr)

-0.59-0.62-0.70-0.78-0.89

FCF after lease payments (INR Cr)

0.85-0.760.090.76-0.14

Cash acquisitions (INR Cr)

0000-0.75

Dividends paid (INR Cr)

00000

Share buybacks (INR Cr)

00000

Net change in cash (INR Cr)

0.17-0.790.240.95-0.49

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, net income / closing equity (%)

56.7-1.1-51.227.80.7

ROA, net income / total assets (%)

24.6-0.5-18.211.60.3

ROIC, EBIT / (equity + debt), zero tax (%)

40.20.1-34.119.7-0.7

Current ratio (x)

3.993.692.102.261.47

Debt/equity incl. leases (x)

0.500.420.530.440.46

Net debt / EBITDA (x)

0.360.63—0.301.12

Interest coverage, EBIT / interest (x)

15.40.0-8.66.8-0.2

Asset turnover (x)

1.080.830.901.261.35

Debtor days

83.959.162.039.025.3

Inventory days, on COGS

15.516.416.715.217.4

Payable days, on COGS

23.314.227.121.928.4

Cash conversion cycle (days)

76.161.351.632.314.3

Income Statement

MetricQ1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue (INR Cr)

4.646.185.415.785.258.095.126.526.17

Net profit (INR Cr)

-0.020.990.310.720.471.84-1.56-0.69-0.04

Revenue by Region and Region Margins & Growth (%)

RegionFY2024FY2025FY2026

India, total (INR Cr)

13.2122.0024.98

Outside India (INR Cr)

000

India growth YoY (%)

-8.766.613.6

Geography Overview

GeographyActivityRevenue disclosed

Mumbai (Ghatkopar and eastern suburbs)

Registered office, flagship centre and lab operations

Not publicly disclosed (assumed to be the large majority)

Navi Mumbai (Turbhe)

Corporate office per 2019 filings

Not applicable

Wider Maharashtra

Collection network and B2B and HLM clients (inferred)

—

Gujarat

Aspira DNA Diagnostics Gujarat LLP (2024), now being struck off

Not publicly disclosed (associate; equity-accounted loss of ₹0.05 Cr in FY2025 per S&P)

“—” = not publicly disclosed.

Share Price & Returns

Reference pointPrice (INR)Source

19 Apr 2024

30.15

Equitymaster

27 Nov 2024

74.44

IndMoney

13 Sep 2025

62.00

Kotak Securities

19 Dec 2025

63.50

ICICIdirect

16 Jan 2026

67.00

Business Standard

21 Apr 2026

56.00

Kotak Neo

16 Jun 2026

117.60

Value Research

29 Jun 2026

130.60

Trendlyne

1 Oct 2026

131.25

IIFL

19 Oct 2026

114.95

StockAnalysis

Return period

Approx. return

Basis

1-year, to Oct 2026

about +85%

From about ₹62 (Sep 2025) to ₹114.95

3-year

Not precisely verified

Business Standard: +62% over 3 years to Jan 2026; since Apr 2024 (₹30.15) about +281%

Lifetime low

₹14.15

Anand Rathi

Valuation Multiples

MultipleAspiraPeer context (aggregator snapshots, 2026)

Market cap (INR Cr)

approx. 118

Dr Lal approx. 32,259; Vijaya approx. 15,511

P/E on FY2026 EPS ₹0.05 (x)

approx. 2,300

Dr Lal approx. 60x; Vijaya approx. 83x

P/B on common equity ₹7.09/share (x)

approx. 16.2

Peer median approx. 3.0x (Value Research)

P/B on aggregator equity ₹11.89/share (x)

approx. 9.7

Value Research shows 9.9x

EV/Sales, EV approx. ₹120 Cr (x)

approx. 4.8

MarketInOut: 5.47x at the Jul 2026 price

EV/EBITDA on FY2026 EBITDA ₹1.46 Cr (x)

approx. 82

MarketInOut: 70.7x; Dr Lal approx. 42x

Capital Markets

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

00000

Buybacks (INR Cr)

00000

Key Events

EventDetail

Nov 2016 preferential issue

29,43,000 shares at ₹17

Sep 2026 rights issue (proposed)

Up to ₹65 Cr, equity or convertibles; price, ratio and record date pending

Capital Markets — Moody's / S&P / Fitch

ItemStatus

Moody's / S&P / Fitch

Not rated

Domestic (CRISIL / ICRA / CARE)

None identified

Debt maturity profile

Total debt ₹3.32 Cr (FY2026): current lease liabilities ₹0.88 Cr due within 12 months; long-term leases ₹1.09 Cr; long-term borrowings ₹1.35 Cr (lender and terms not disclosed; may be related-party)

Analyst Conclusions

Management Guidance and Consensus

No quantitative guidance has been issued and no consensus exists. Qualitative direction includes regional consolidation, an HLM focus, digital engagement, and, implicitly, scale-up funded by the proposed rights issue.

Bull Case

  1. Capital step-change. A fully subscribed ₹65 Cr rights issue would give a company with about ₹7 Cr of common equity the means to acquire Mumbai standalone labs or build HLM capacity. This could plausibly multiply revenue from the current ₹25 Cr base, much as the 2016 Ankur Pathology deal created the business.

  2. Operating leverage is proven. In FY2025, revenue of ₹22 Cr produced 9.4% EBIT margin and ₹2.0 Cr PAT. Q1 FY2027 revenue of ₹6.17 Cr (annualising to about ₹25 Cr) was already near breakeven. Modest revenue growth with cost discipline could restore FY2025-level margins, untaxed thanks to accumulated losses.

  3. Aligned, committed owners. The new promoter group invested ₹12.55 Cr in cash at ₹55 per share, now holds 46.58%, and continues buying on the open market. This suggests intent to build rather than extract value.

Bear Case

  1. Structurally unprofitable at scale. FY2026 showed that growth (+13.6%) came with a 36% cost surge and a 97.6% profit fall. Two loss quarters indicate the business has not yet found a profitable growth formula against far larger rivals.

  2. Governance and dilution. Concentrated control, a ₹5 Cr related-party arrangement with Yashraj Research Foundation, company-secretary turnover, and an undisclosed use of proceeds for a rights issue about half the market cap together create meaningful minority-shareholder risk.

  3. Valuation disconnect. At about ₹115 the stock trades at roughly 2x the ₹55 offer price set only six months earlier, about 2,300x FY2026 EPS, 80x+ EV/EBITDA and 10–16x book. This prices in a transformation that has not begun, in an illiquid stock.

Key Catalysts and Monitorables (next 12 months)

Catalyst / monitorableWhat to watch
Rights issue termsPrice, ratio, record date and stated objects (acquisitions? related-party assets?); promoter subscription and renunciation
Q2 FY2027 results (Nov 2026)Whether the cost base stabilises after the leadership change; revenue run-rate above ₹6 Cr per quarter
Clinical leadershipAppointment of a senior pathologist / medical director after Dr Shah's exit
Compliance officer appointmentFilling the CS vacancy
Related-party transactionsActual flows to Yashraj entities versus the approved ₹5 Cr limit
HLM contract winsAny named hospital contracts disclosed under Reg. 30
Share capital reconciliationWhether paid-up capital remains ₹10.29 Cr or has changed (registry shows ₹15.79 Cr)
AccreditationConfirmation of NABL status

Analyst Verdict

Aspira Pathlab & Diagnostics is a speculative special situation, not a diagnostics growth compounder. The underlying business is real but small. A Mumbai pathology and radiology operator turned over ₹24.98 Cr in FY2026, generates modestly positive operating cash, and has shown it can earn a high-single-digit operating margin when volumes cooperate, as in FY2025. It has also shown that margins evaporate quickly when costs run ahead of revenue: FY2026 profit fell 97.6%, with back-to-back loss quarters in the second half.

The investment case has shifted decisively from operations to ownership and capital. The Bhanushali–Mange group's ₹55 open offer gave it 46.58% control. The founder-MD has left, Nikunj Mange now runs the company, and a rights issue of up to ₹65 Cr is on the table, roughly nine times current common equity. Done well, this capital could fund a disciplined roll-up of Mumbai's fragmented standalone labs and an HLM platform, turning a sub-scale lab into a credible regional player. Done poorly, it could fund related-party asset purchases or unfocused expansion, diluting minorities in a stock with no institutional oversight.

The market has priced the optimistic version. At about ₹115, the shares trade at more than twice the price the controlling group paid six months ago, at multiples that only make sense if revenue and margins multiply. Disclosure quality is low, with no guidance, segment data or test-volume metrics, and related-party exposure has risen. For institutional capital, the stock is effectively uninvestable on liquidity and governance grounds until the rights-issue objects are published and at least two quarters of post-transition results are available. For risk-tolerant investors, the rights-issue offer document is the single most important document to read. The verdict is Neutral-to-Cautious / Speculative, with re-assessment triggered by the rights-issue terms and the Q2–Q3 FY2027 results.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation (latest disclosed)

Nikunj Velji Mange

Managing Director (re-designation approved at 53rd AGM, 25 Sep 2026); previously Executive Director; promoter since Jun 2026

—

Open-offer Acquirer 4; spouse Shraddha Nikunj Mange was the PAC

—

Vaibhav Odhekar

Executive Director (regularised at 2026 AGM)

2,026——

Dr Pankaj Jashwant Shah

Former MD & CEO; resigned effective 3 Aug 2026 (personal reasons)

Executive Director from 1 Aug 2016; CEO from 13 Jun 2020; MD re-appointed for 3 years from 1 Aug 2022

Pathologist; led the business since the 2016 Ankur Pathology acquisition

₹6.0 million total (100% salary) per Simply Wall St (FY2025); held 4.86% of shares

Chief Financial Officer

——

Not identified in sources reviewed

—

Company Secretary & Compliance Officer

Resigned early 2026; successor not identified

———

Dr C. P. Puri (historical)

CEO, 2017–2019 (also CEO of Yashraj Biotechnology)

2017–2019

Former Director, ICMR's National Institute for Research in Reproductive Health

Not applicable

“—” = not publicly disclosed.

Board of Directors

NameRoleIndependenceNotes

Dr Haseeb A. Drabu

Chairman

Independent

Economist; former Finance Minister of Jammu & Kashmir and former Chairman of J&K Bank (public record)

Nikunj Velji Mange

Managing Director

Executive / Promoter

See above

Vaibhav Odhekar

Executive Director

Executive

Regularised Sep 2026

Manas Mengar (DIN 10218206)

Director

Independent

Appointed at 50th AGM, 26 Sep 2023

Avinash Mahajan

Director

Independent

Re-appointed for a 5-year term from 25 Sep 2022 (to 2027)

Former Maharashtra public-health official (name not captured)

Director

Independent

Board-appointed 13 Aug 2022; career from Deputy Director to Director General, Maharashtra Health Services; prior WHO regional advisory roles per filing

"Mangala" and "Subhash" (surnames not captured)

Directors

—

Listed by a company-registry aggregator as active directors

Board & Management Changes

DateChangeContext

Early 2026

Company Secretary cum Compliance Officer resigned

During open-offer process

11 Jun 2026

Nikunj Mange and Jay Arvind Bhanushali reclassified as promoters

Post open offer, under SEBI rules

3 Aug 2026

Dr Pankaj Shah resigned as MD

Personal reasons; founder-operator exit after about 10 years

25 Sep 2026

Nikunj Mange re-designated MD; Vaibhav Odhekar regularised as Executive Director

New control group takes operating leadership

Shareholding Trend

Holder categoryMar 2023Mar 2024Mar 2025Mar 2026Jun 2026

Promoter & promoter group (%)

19.4718.7218.3918.3946.58

FII (%)

00000

DII / mutual funds (%)

00000

Public (%)

80.5381.2881.6181.6153.42

Major Shareholders

HolderStakeAs ofCategory

Deepali Arvind Bhanushali

8.6%

Mar 2026 (pre-offer; post-offer higher)

Promoter

Rinku Vinod Bhanushali

8.02%

Mar 2026

Public (largest public holder)

Jay Arvind Bhanushali

7.27%

Sep 2026

Promoter (open-market purchases Sep 2026)

Arvind Karsandas Bhanushali

——

Promoter / lead acquirer

Dr Pankaj Shah

4.86%2,025

Insider (former MD)

Nikunj Velji Mange

2.14% pre-offer

2025–26

Promoter

Shraddha Nikunj Mange

1.46% pre-offer

2025–26

Promoter group (PAC)

Raj Arvind Bhanushali

0.76% pre-offer

2025–26

Promoter

Yashraj Biotechnology Ltd

——

Historical promoter-group entity

Competitive Landscape

Peer Comparison FY2025

CompetitorTypeRelevance to AspiraApprox. scale (FY2025 revenue)Market cap (aggregator snapshot, 2026)

Dr Lal PathLabs

Listed national chain

Strong Mumbai presence via B2C and B2B network

approx. ₹2,460 Cr

approx. ₹32,259 Cr

Metropolis Healthcare

Listed national chain, Mumbai-headquartered

Most direct home-market rival

approx. ₹1,330 Cr

Not captured

Thyrocare Technologies

Listed national chain, Navi Mumbai-headquartered

B2B / franchise wholesale testing

approx. ₹690 Cr

Not captured

Vijaya Diagnostic Centre

Listed regional chain (South India)

Model peer for a regional strategy

approx. ₹680 Cr

approx. ₹15,511 Cr

Krsnaa Diagnostics

Listed (PPP / government-focused)

Competes for institutional / HLM-type contracts

approx. ₹720 Cr

Not captured

Agilus Diagnostics (ex-SRL, Fortis group)

Unlisted subsidiary of listed Fortis

Hospital-lab and B2B competitor

—

Not applicable

Apollo Diagnostics

Hospital-group diagnostics

Hospital and retail competitor

—

Not applicable

Suburban Diagnostics

Mumbai regional chain

Direct Mumbai B2C competitor

—

Not applicable

Neuberg Diagnostics

Private national network

B2B / reference lab

—

Not applicable

Tata 1mg Labs, Healthians, Redcliffe Labs, Orange Health

Digital-first home-collection players

Compete for B2C home collection

—

Not applicable

Standalone neighbourhood labs (Mumbai)

Fragmented local operators

Largest competitive set by count

Not applicable

Not applicable

Peer Comparison FY2026

MetricAspira (FY2026)Dr Lal PathLabs (FY2025, approx.)Metropolis (FY2025, approx.)Thyrocare (FY2025, approx.)

Revenue (INR Cr)

24.98

approx. 2,460

approx. 1,330

approx. 690

Revenue growth (%)

13.6

approx. 10–11

approx. 10–11

approx. 14–15

EBITDA margin (%)

5.9

approx. 27–28

approx. 24–25

approx. 26–28

Net margin (%)

0.2

approx. 19–20

approx. 10–11

approx. 14–15

R&D intensity (%)

—

Not material

Not material

Not material

Market cap (INR Cr)

approx. 118

approx. 32,000

Not captured

Not captured

“—” = not publicly disclosed.

Company Snapshot

$2.9M

Revenue

141

Employees

$14M

Market Cap

1973

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Demonstrated revenue rebound. Revenue rose 66.6% in FY2025 (₹13.21 Cr to ₹22.00 Cr) and a further 13.6% in FY2026 (₹24.98 Cr), with Q1 FY2027 up about 17.6% YoY (₹6.17 Cr).
  • Collections discipline. Debtor days fell from 84 (FY2022) to 25 (FY2026), and the cash conversion cycle shrank from 76 to 14 days.
  • Low leverage. Net debt is only about ₹1.6 Cr (FY2026), mostly lease liabilities; debt/equity is about 0.46x including leases.
  • Consistently positive operating cash flow. OCF was ₹1.0–2.0 Cr in four of five years, despite accounting losses in FY2024.
  • Committed controlling shareholder. The acquirer group spent ₹12.55 Cr in the open offer to lift its stake to about 46%, and a promoter made further open-market purchases in September 2026.
  • Independent chair. Dr Haseeb Drabu, a former state finance minister, separates the board chair from management.

Weaknesses

  • Profit collapse. FY2026 PAT fell 97.6% to ₹0.05 Cr as operating expenses excluding COGS rose 36% against 6.6% gross-profit growth.
  • Extreme sub-scale. Revenue of ₹24.98 Cr is about 1% of Dr Lal PathLabs' and about 2% of Metropolis's.
  • Accumulated deficit. Retained earnings of -₹12.0 Cr (FY2026) block dividends and reflect the shell-company legacy.
  • Thin free cash flow after leases. FCF after lease payments was -₹0.14 Cr in FY2026 and -₹0.76 Cr in FY2023.
  • Disclosure gaps. There are no segment, test-volume, centre-count or payer-mix disclosures, no investor presentations and no earnings calls. A company-secretary resignation in early 2026 adds to compliance gaps.
  • Leadership discontinuity. The founder-pathologist MD resigned on 3 Aug 2026, about 10 years after building the business.

Opportunities

  • Rights issue capital. Up to ₹65 Cr would multiply the equity base (common equity about ₹7.3 Cr) roughly ninefold, enabling acquisitions, new labs or HLM build-out.
  • HLM pipeline. New hospital capacity in MMR offers recurring B2B contracts (management-stated focus).
  • Consolidation of Mumbai standalone labs. The company has precedent from its own 2016 entry via the Ankur Pathology acquisition.
  • Operating leverage. At FY2025's 9.4% EBIT margin on ₹22 Cr, every incremental ₹5 Cr of revenue at a 40% gross margin could add about ₹2 Cr of EBIT if the cost base holds.
  • Tax shield. Accumulated losses mean near-term profits are largely tax-free (the tax charge has been nil for five years).
  • Preventive and digital channels. Engagement tools already launched (chatbot, patient platform) can be scaled with fresh capital.

Threats

  • Price war in Mumbai. Metropolis and Thyrocare are headquartered in the region, and Dr Lal and digital players are expanding.
  • Related-party concentration. A ₹5 Cr transaction with Yashraj Research Foundation was approved in February 2026, about 20% of FY2026 revenue. With control now concentrated, minority-protection risk rises.
  • Dilution risk. A ₹65 Cr rights issue against a market cap of about ₹118 Cr implies large dilution for shareholders who do not subscribe.
  • Valuation risk. P/E is above 2,000x on FY2026 EPS of ₹0.05, and P/B is about 9–16x depending on equity definition. Shares rose about 134% in two months after the offer.
  • Liquidity risk. Daily BSE volumes are often in the tens to low thousands of shares, so exits can move the price sharply.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 May 2025Board meeting for Q4 / FY2025 resultsFY2025 turnaround: revenue ₹22.00 Cr, PAT ₹2.02 Cr
12 Aug 2025Q1 FY2026 results: revenue ₹5.25 Cr, consolidated PAT ₹0.42–0.47 CrProfit up sharply YoY (about 740% per Capital Market)
Aug–Sep 202552nd AGM convened (FY2025)Routine
26 Sep 2025Open offer public announcement: 26% at ₹55 by five acquirers plus PACChange-of-control trigger
13 Oct 2025Draft Letter of Offer filed with SEBIRegulatory step
12 Nov 2025Q2 FY2026 results: revenue ₹8.09 Cr, net profit ₹1.84 Cr (net profit up about 86% YoY per Capital Market)Record quarter
Dec 2025Share trades about ₹63–64; P/E about 27x on TTMPre-offer valuation baseline
10 Feb 2026Q3 FY2026: revenue ₹5.12 Cr (down 5.3% YoY); net loss ₹1.56 Cr; 9M PAT ₹0.74 Cr (down 45%)Sharp profit reversal
10 Feb 2026Board approves related-party transaction of up to ₹5 Cr with Yashraj Research FoundationGovernance monitorable
Early 2026Company Secretary cum Compliance Officer resignsCompliance continuity risk
27 Mar 2026Record date for open offerProcess milestone
14–15 Apr 2026Compliance certificate filed; company confirms it is not a "Large Corporate" under SEBI frameworkRoutine
15–28 Apr 2026Open-offer tendering period (one report cites 15 Apr – 13 May; adopted dates follow post-offer advertisement)Shareholders tender 22.18%
21 Apr 2026Stock about ₹56, near offer price; down about 17.6% YoYPrice anchored to offer
May 2026Board approves acquiring 100% of Aspira DNA Diagnostics Gujarat LLP and striking it offExit from Gujarat venture
18 May 2026Post-offer advertisement: 22,82,507 shares acquired for ₹12.55 CrOffer concluded
23–24 May 2026FY2026 results: revenue ₹24.98 Cr (+13.6%); PAT ₹0.05 Cr (-97.6%); Q4 loss ₹0.69 CrMargin collapse
8 Jun 2026Acquirer group stake reaches 46.00% (from 23.82%)Control consolidated
11 Jun 2026Nikunj Mange and Jay Bhanushali reclassified as promotersPromoter-group redefinition
Jun–Jul 2026Share rallies to about ₹118–131 (up about 134% in two months per MarketInOut)Re-rating on control change
3 Aug 2026MD Dr Pankaj Shah resigns (personal reasons)Founder-operator exit
6 Aug 2026Board meeting notice: Q1 results and fund-raise options (equity, warrants, preferential, QIP, rights)Capital-raise signal
12 Aug 2026Q1 FY2027: revenue ₹6.17 Cr (+17.6% YoY); net loss ₹3.77 lakhNear-breakeven; sequential improvement
10–16 Sep 2026Promoter Jay Bhanushali buys small lots in the open market (74 and 1,387 shares); stake 7.25% to 7.27%Signalling purchases
12 Sep 2026Board approves rights issue of up to ₹65 Cr; Rights Issue Committee formedTransformational capital raise
25 Sep 202653rd AGM: Nikunj Mange re-designated MD; Vaibhav Odhekar regularised as ED; related-party transactions approvedNew leadership formalised
1 Oct 2026Share at ₹131.25Near 52-week high
19 Oct 2026Share closes at ₹114.95 (-4.96% on the day)Volatile, thinly traded

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 195.4 Mn in FY2022 to INR 249.8 Mn in FY2026.
Aspira Pathlab & Diagnostics Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations195.4144.6132.1220249.8
Cost of revenue95.688.697.9122.9146.3
Gross profit99.855.934.297.1103.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1BSE corporate filings (bseindia.com): AR FY2018-19 cover letter; AR FY2021-22 (Aug 2022); Reg. 30 disclosures May 2022, Aug 2022, Sep 2023; RPT disclosures 2019–2020 — Legal identity, CIN, offices, directors, RTA, history
  2. 2SEBI open-offer documents: Public Announcement (Oct 2025 folder), Draft Letter of Offer (Nov 2025), Letter of Offer (Apr 2026) — Open-offer terms, acquirers, PAC
  3. 3StockAnalysis.com (S&P Global Market Intelligence data; income statement, balance sheet, cash flow; updated 12 Aug 2026) — 5-year financials, price 19 Oct 2026
  4. 4Screener.in (standalone and consolidated pages) — FY2024–25 consolidated P&L, debtor days, announcements (LLP strike-off, promoter reclassification)
  5. 5Medical Buyer / Capital Market (May 2026) — Q4 and FY2026 results
  6. 6ScanX (multiple articles 2025–26) — Q3 FY2026, Q1 FY2027, open-offer completion, AGM outcome, shareholding history, rights issue
  7. 7Whalesbook (Apr–Sep 2026) — Open-offer stake change, FY2026 profit, AGM agenda
  8. 8IndiaIPO / ScanX post-offer advertisement coverage — Acceptance figures and offer size
  9. 9Value Research (BSE board-outcome reproduction, 12 Sep 2026; stock page Jun 2026) — Rights issue details; market cap, P/B
  10. 10Groww — MD resignation, promoter purchases, shareholding
  11. 11Trendlyne shareholding pages — Historical promoter composition, board-meeting dates
  12. 12Simply Wall St — CEO tenure, compensation, ownership, analyst coverage
  13. 13IIFL / Kotak Securities / Kotak Neo company summaries — Corporate history, Ankur Pathology acquisition, LLP formation, quarterly data
  14. 14roic.ai — Q2 FY2026 figures; network expansion claim (600+ centres, 91 added)
  15. 15PitchBook profile — Employee count (141), HQ
  16. 16Business Standard / Capital Market — Q3 FY2022 results; price and returns Jan 2026
  17. 17MarketInOut, IndMoney, ICICIdirect, Equitymaster, Anand Rathi, Fyers — Price history, valuation ratios, peer snapshot
  18. 18MarketScreener insider profile — Dr C. P. Puri CEO tenure
  19. 19Registerkaro / Infyner company-registry aggregators — Incorporation date, paid-up and authorised capital, director names, employee estimate

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.